Active, not recruitingPhase 1NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Azacitidine(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States
- The University of Chicago Medical Center /ID# 153673, Chicago, Illinois, United States
- University of Maryland, Baltimore /ID# 153669, Baltimore, Maryland, United States
- Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States
- Washington University-School of Medicine /ID# 153671, St Louis, Missouri, United States
- Columbia University Medical Center /ID# 153661, New York, New York, United States
- Weill Cornell Medical College /ID# 155524, New York, New York, United States
- Oregon Medical Research Center /ID# 152734, Portland, Oregon, United States
- University of Pittsburgh MC /ID# 153662, Pittsburgh, Pennsylvania, United States
- Tennessee Oncology-Nashville Centennial /ID# 222769, Nashville, Tennessee, United States
- Vanderbilt University Medical Center /ID# 152738, Nashville, Tennessee, United States
- UT MD Anderson Cancer Center /ID# 153809, Houston, Texas, United States
- Concord Repatriation General Hospital /ID# 154958, Concord, New South Wales, Australia
- Duplicate_St. Vincent's Hospital, Darlinghurst /ID# 222846, Darlinghurst, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02942290 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07384715First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Genmab
- RECRUITINGPHASE1NCT06670222Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)Groupe Francophone des Myelodysplasies
- RECRUITINGPHASE1NCT06552416Safety of MT-401-OTS in Patients With Relapsed AML or MDSMarker Therapeutics, Inc.
- RECRUITINGNANCT07121140Home Blood TransfusionsThomas Jefferson University
- RECRUITINGNANCT05924074Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)University Hospital, Bordeaux
- RECRUITINGNCT06379945Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)Instituto de Investigación Biomédica de Salamanca
- RECRUITINGPHASE1, PHASE2NCT05181735Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESAGroupe Francophone des Myelodysplasies
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04798339Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAH. Lee Moffitt Cancer Center and Research Institute